Outlook Therapeutics Inc. (NASDAQ: OTLK) Stock Information | RedChip

Outlook Therapeutics Inc. (NASDAQ: OTLK) Listen to this Section


$7.69
+0.0100 ( +0.13% ) 197.7K

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Market Data


Open


$7.69

Previous close


$7.68

Volume


197.7K

Market cap


$180.46M

Day range


$7.48 - $8.06

52 week range


$4.00 - $29.20

Insider Ownership Transactions

Total Amount Purchased: -2,302,885.29 | $ -17,709,187.88

Date Type Amount Purchased Purchaser
2024-04-17 Buy 714286.00 Syntone Ventures LLC
2024-03-29 Buy 1881.71 Haddadin Yezan Munther
2024-03-22 Sale -12500.00 KENYON LAWRENCE A
2024-03-22 Sale -25000.00 Evanson Jeff
2024-03-22 Sale -455000.00 TRENARY C RUSSELL III
2024-03-20 Sale -2305714.00 Sukhtian Ghiath M.
2024-03-11 Buy 62484.00 Evanson Jeff
2024-03-08 Sale -94441.00 Haller Julia A
2024-03-08 Sale -94441.00 Auffarth Gerd
2024-03-08 Sale -94441.00 Huang Andong

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 15 Aug 14, 2024
10-q Quarterly Reports 71 Aug 14, 2024
8-k 8K-related 13 Jul 08, 2024
def Proxies and info statements 6 Jun 26, 2024
pre Proxies and info statements 6 Jun 14, 2024
8-k 8K-related 13 May 28, 2024
10-q Quarterly Reports 69 May 15, 2024
8-k 8K-related 15 May 15, 2024
8-k 8K-related 15 May 13, 2024
8-k 8K-related 14 May 01, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.